MedTrace Logo

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

NCT03336593 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 810

Last updated 2019-04-02

No results posted yet for this study

Summary

This study is to assess protectivity and safety of Quadrivalent Influenza Vaccine in Indonesian Population

Conditions

  • Safety Issues

Interventions

BIOLOGICAL

Quadrivalent Influenza Vaccine

1 or 2 doses of Quadrivalent Influenza Vaccine depends on age

BIOLOGICAL

Trivalent Influenza Vaccine

1 dose of Trivalent Influenza Vaccine

Sponsors & Collaborators

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Meita Dhamayanti · Hasan Sadikin General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-21
Primary Completion
2018-03-14
Completion
2018-11-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03336593 on ClinicalTrials.gov